Talazoparib (BMN 673)

Catalog No.S7048 Batch:S704808

Print

Technical Data

Formula

 

C19H14F2N6O
 
Molecular Weight 380.35 CAS No. 1207456-01-6
Solubility (25°C)* In vitro DMSO 76 mg/mL (199.81 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Talazoparib (BMN 673, LT-673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.
Targets
PARP1 [1]
(Cell-free assay)
0.57 nM
In vitro

BMN-673 selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. BMN 673 selectively kills cancer cells with BRCA-1 or BRCA-2 mutations. BMN 673 demonstrates single-agent cytotoxicityin BRCA-1 mutant (MX-1, IC50 = 0.3 nM) and BRCA-2 mutant cells (Capan-1, IC50 = 5 nM). In contrast, in MRC-5 normal human fibroblastand other tumor cell lines with wild-type BRCA-1 and BRCA-2 genes, IC50 of BMN 673 ranges between 90 nM and 1.9 μM. [1]

Off-target molecular screening did not identify significant non-specific activity for this class of PARP inhibitors. [2]
In vivo

In rat pharmacokinetic studies, BMN 673 displays >50% oralbioavailability and pharmacokinetic properties that enable singledaily dosing. In MX-1 xenograft tumor model studies, daily oral dosingof BMN 673 significantly enhances the antitumor effects ofcytotoxic therapies in a dose-dependent manner. [2]
Features Most potent and selective PARPi reported thus far.

Protocol (from reference)

Cell Assay:

[3]
  • Cell lines

    MDA-MB-436 cells

  • Concentrations

    10 uM

  • Incubation Time

    7 days

  • Method

    Cells were treated with increasing doses of talazoparib for 7 days and subjected to cell viability assays to derive IC50 values.
Animal Study:

[2]
  • Animal Models

    MX-1 model (BRCA-1 deficient)

  • Dosages

    0.33 mg/kg/day, once daily

  • Administration

    Oral

Customer Product Validation

, , Clin Cancer Res, 2017, 23(13):3405-3415

Data from [Data independently produced by , , Nature, 2018, 559(7713):285-289]

Data from [Data independently produced by , , Clin Cancer Res, 2017, 23(14):3711-3720]

Data from [Data independently produced by , , J Neuroinflammation, 2016, 13(1):254.]

Selleck's Talazoparib (BMN 673) has been cited by 255 publications

Transcription-replication conflicts underlie sensitivity to PARP inhibitors [ Nature, 2024, 10.1038/s41586-024-07217-2] PubMed: 38509368
Transcription-replication conflicts underlie sensitivity to PARP inhibitors [ Nature, 2024, 628(8007):433-441] PubMed: 38509368
Dual Inhibition of CDK4/6 and XPO1 Induces Senescence With Acquired Vulnerability to CRBN-Based PROTAC Drugs [ Gastroenterology, 2024, S0016-5085(24)00062-3] PubMed: 38262581
GRB2 stabilizes RAD51 at reversed replication forks suppressing genomic instability and innate immunity against cancer [ Nat Commun, 2024, 15(1):2132] PubMed: 38459011
Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors [ Nat Commun, 2024, 15(1):2862] PubMed: 38580648
PARP1-dependent DNA-protein crosslink repair [ Nat Commun, 2024, 15(1):6641] PubMed: 39103378
H2AX promotes replication fork degradation and chemosensitivity in BRCA-deficient tumours [ Nat Commun, 2024, 15(1):4430] PubMed: 38789420
BRCA1 levels and DNA-damage response are controlled by the competitive binding of circHIPK3 or FMRP to the BRCA1 mRNA [ Mol Cell, 2024, S1097-2765(24)00773-1] PubMed: 39389065
The MYCN oncoprotein is an RNA-binding accessory factor of the nuclear exosome targeting complex [ Mol Cell, 2024, S1097-2765(24)00285-5] PubMed: 38703770
DNA-PK participates in pre-rRNA biogenesis independent of DNA double-strand break repair [ Nucleic Acids Res, 2024, gkae316] PubMed: 38682589

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.